Abstract:Mesenchymal stromal cells (MSCs) are an attractive option for cell therapy for type 1 diabetes mellitus (DM). These cells can be obtained from many sources, but bone marrow and adipose tissue are the most studied. MSCs have distinct advantages since they are nonteratogenic, nonimmunogenic and have immunomodulatory functions. Insulin-producing cells (IPCs) can be generated from MSCs by gene transfection, gene editing or directed differentiation. For directed differentiation, MSCs are usually cultured in a glucose-rich medium with various growth and activation factors. The resulting IPCs can control chemically-induced diabetes in immune-deficient mice. These findings are comparable to those obtained from pluripotent cells. PD-L1 and PD-L2 expression by MSCs is upregulated under inflammatory conditions. Immunomodulation occurs due to the interaction between these ligands and PD-1 receptors on T lymphocytes. If this function is maintained after differentiation, life-long immunosuppression or encapsulation could be avoided. In the clinical setting, two sites can be used for transplantation of IPCs: the subcutaneous tissue and the omentum. A 2-stage procedure is required for the former and a laparoscopic procedure for the latter. For either site, cells should be transplanted within a scaffold, preferably one from fibrin. Several questions remain unanswered. Will the transplanted cells be affected by the antibodies involved in the pathogenesis of type 1 DM? What is the functional longevity of these cells following their transplantation? These issues have to be addressed before clinical translation is attempted. Graphical Abstract Bone marrow MSCs are isolated from the long bone of SD rats. Then they are expanded and through directed differentiation insulin-producing cells are formed. The differentiated cells are loaded onto a collagen scaffold. If one-stage transplantation is planned, a drug delivery system must be incorporated to ensure immediate oxygenation, promote vascularization and provide some growth factors. Some mechanisms involved in the immunomodulatory function of MSCs. These are implemented either by cell to cell contact or by the release of soluble factors. Collectively, these pathways results in an increase in T-regulatory cells.

Generation of Insulin-Producing Cells from PDX-1 Gene-Modified Human Mesenchymal Stem Cells.

Generation of Insulin-Producing Cells from Bone Marrow Mesenchymal Stem Cells with Modified Expression of PDX1 and NKX6.1

Generation of Insulin-Producing Cells from PDX1 and NKX6.1 Gene-Modified Bone Marrow Mesenchymal Stem Cells

Generation of Insulin-Producing Cells from C3H10T1/2 Mesenchymal Progenitor Cells

Generation of insulin-producing cells from C3H10T1/2 mesenchymal progenitor cells.

Human bone marrow mesenchymal stem cells differentiate into insulin-producing cells upon microenvironmental manipulation in vitro.

Human Expandable Pancreatic Progenitor–derived Β Cells Ameliorate Diabetes

PDX1 gene and cytokines induce human umbilical cord mesenchymal stem cells to differentiate into islet β-like cells in vitro

Generation of Pancreatic Insulin-Producing Cells from Rhesus Monkey Induced Pluripotent Stem Cells

Treatment of Type 1 Diabetes with Adipose Tissue-Derived Stem Cells Expressing Pancreatic Duodenal Homeobox 1.

Overexpression of Ngn3 and Pdx-1 in Human Bone Marrow Derived Mesenchymal (Hmsc-Tert) Stem Cells Triggers Endocrine Pancreatic Gene Expression

Insulin-Producing Cells Differentiated from Human Bone Marrow Mesenchymal Stem Cells in Vitro Ameliorate Streptozotocin-Induced Diabetic Hyperglycemia

Bone Marrow Mesenchymal Stem Cells Orthotopictransplantation Reverse Diabetes

Coexpression of Pdx1 and betacellulin in mesenchymal stem cells could promote the differentiation of nestin-positive epithelium-like progenitors and pancreatic islet-like spheroids.

From Mesenchymal Stromal/Stem Cells to Insulin-Producing Cells: Progress and Challenges

In Vivo And In Vitro Characterization Of Insulin-Producing Cells Obtained From Murine Bone Marrow

In vitro generation of functional insulin-producing cells from human bone marrow-derived stem cells, but long-term culture running risk of malignant transformation.

The expression of PDX-1 gene in mesenchymal stem cells transduced by adenovirus vector

Studies on Coexpression of PDX1 and Betacellulin in Bone Marrow Mesen-chymal Stem Cells Differentiating into Insulin-secreting Cells

In vitro derivation of functional insulin-producing cells from human embryonic stem cells

Generation of Functional Insulin-Producing Cells from Human Embryonic Stem Cells in Vitro